These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21497188)

  • 1. Predicting solution aggregation rates for therapeutic proteins: approaches and challenges.
    Roberts CJ; Das TK; Sahin E
    Int J Pharm; 2011 Oct; 418(2):318-33. PubMed ID: 21497188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Principles, approaches, and challenges for predicting protein aggregation rates and shelf life.
    Weiss WF; Young TM; Roberts CJ
    J Pharm Sci; 2009 Apr; 98(4):1246-77. PubMed ID: 18683878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational methods to predict therapeutic protein aggregation.
    Buck PM; Kumar S; Wang X; Agrawal NJ; Trout BL; Singh SK
    Methods Mol Biol; 2012; 899():425-51. PubMed ID: 22735968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulation and manufacturability of biologics.
    Shire SJ
    Curr Opin Biotechnol; 2009 Dec; 20(6):708-14. PubMed ID: 19880308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting accelerated aggregation rates for monoclonal antibody formulations, and challenges for low-temperature predictions.
    Brummitt RK; Nesta DP; Roberts CJ
    J Pharm Sci; 2011 Oct; 100(10):4234-43. PubMed ID: 21671226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosage form design and development.
    Allen LV
    Clin Ther; 2008 Nov; 30(11):2102-11. PubMed ID: 19108798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formulation and Stability of Solutions.
    Akers MJ
    Int J Pharm Compd; 2016; 20(1):41-5. PubMed ID: 27127830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A framework for in-silico formulation design using multivariate latent variable regression methods.
    Polizzi MA; García-Muñoz S
    Int J Pharm; 2011 Oct; 418(2):235-42. PubMed ID: 21569826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein aggregation--pathways and influencing factors.
    Wang W; Nema S; Teagarden D
    Int J Pharm; 2010 May; 390(2):89-99. PubMed ID: 20188160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of drug physical form during granulation, tabletting and storage.
    Williams AC; Cooper VB; Thomas L; Griffith LJ; Petts CR; Booth SW
    Int J Pharm; 2004 May; 275(1-2):29-39. PubMed ID: 15081136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discrete element method (DEM) simulations of stratified sampling during solid dosage form manufacturing.
    Hancock BC; Ketterhagen WR
    Int J Pharm; 2011 Oct; 418(2):265-72. PubMed ID: 21635943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How native proteins aggregate in solution: a dynamic Monte Carlo simulation.
    Zhang L; Lu D; Liu Z
    Biophys Chem; 2008 Mar; 133(1-3):71-80. PubMed ID: 18206291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NMR in drug discovery.
    Pellecchia M; Sem DS; Wüthrich K
    Nat Rev Drug Discov; 2002 Mar; 1(3):211-9. PubMed ID: 12120505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase transformation considerations during process development and manufacture of solid oral dosage forms.
    Zhang GG; Law D; Schmitt EA; Qiu Y
    Adv Drug Deliv Rev; 2004 Feb; 56(3):371-90. PubMed ID: 14962587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular modeling of hydration in drug design.
    Mancera RL
    Curr Opin Drug Discov Devel; 2007 May; 10(3):275-80. PubMed ID: 17554853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Lumry-Eyring nucleated polymerization model of protein aggregation kinetics: 1. Aggregation with pre-equilibrated unfolding.
    Andrews JM; Roberts CJ
    J Phys Chem B; 2007 Jul; 111(27):7897-913. PubMed ID: 17571872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developing early formulations: practice and perspective.
    Li P; Zhao L
    Int J Pharm; 2007 Aug; 341(1-2):1-19. PubMed ID: 17658228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The formulation and immunogenicity of therapeutic proteins: Product quality as a key factor.
    Richard J; Prang N
    IDrugs; 2010 Aug; 13(8):550-8. PubMed ID: 20721826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physics-based methods for studying protein-ligand interactions.
    Huang N; Jacobson MP
    Curr Opin Drug Discov Devel; 2007 May; 10(3):325-31. PubMed ID: 17554859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.